. 2022 Dec 31;24(1):707. doi: 10.3390/ijms24010707

Table 1.

Investigation of the SCFAs in the AD patients and in the animal models of AD.

Subjects	Number of Subjects	Sex	Reference
AD patients	17	5 Males/12 Females	[7]
AD patients	77	38 Males/39 Females	[10]
APP/PS1 mice 3×Tg-AD mice	30 8	13 Males/17 Females	[16]
APP/PS1 mice 3×Tg-AD mice	30 8	n.i.	[16]
3×Tg-AD mice	4	n.i.	[17]
3×Tg-AD mice	16	0 Males/16 Females	[18]
APP/PS1 mice	56	n.i.	[19]
APP/PS1 mice	6	6 Males/0 Females	[20]
APP/PS1 mice	8	n.i.	[25]
SAMP-8 mice	24	24 Males/0 Females	[26]
3×Tg-AD mice	8	0 Males/8 Females	[27]
AD patients	89	41 Males/48 Females	[28]

APP/PS1: amyloid precursor protein/presenilin 1, 3×Tg-AD (triple transgenic-Alzheimer’s disease), SAMP-8: senescence-accelerated prone-8. n.i.: not provided information.